AACR sees Quantum-Si push protein sequencing to uncover new cancer therapies

AACR sees Quantum-Si push protein sequencing to uncover new cancer therapies
Quantum-Si details cancer tech at AACR

Quantum-Si announced live developments in next-generation protein sequencing at the AACR conference, with Dr. Nigel O'Neil, founder and CSO of Arrowsmith Genetics, presenting strategies for identifying novel cancer treatments.

Attendees are invited to engage further at the event's poster session and booth 4257, where the application of cutting-edge protein sequencing in cancer research is being discussed.

Quantum-Si recently introduced single molecule sequencing to enhance post-translational modification detection in protein analysis workflows. The company also unveiled a protein sequencing platform capable of single-amino-acid resolution from nanogram-scale samples. Both advances point to growing interest in high-resolution protein sequencing applications in cancer research.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.